Trial reportMolecular medicine (Cambridge, Mass.)2013
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.
Trial report in Molecular medicine (Cambridge, Mass.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- [The EAN-NeuPSIG guideline on the diagnosis of neuropathic pain-a summary].Schmerz (Berlin, Germany) · 2026Guideline
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.) · 2015Trial
- Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.Current pain and headache reports · 2026Review
- Quality of Life in Sarcoidosis.Diagnostics (Basel, Switzerland) · 2026Review
- Non-hematopoietic roles of erythropoietin in inflammation and metabolic disorders.Frontiers in pharmacology · 2025Review
- Shedding light on neuropathic pain: Current and emerging tools for diagnosis, screening, and quantification.SAGE open medicine · 2024Review
- Article
- Artificial Intelligence and Corneal Confocal Microscopy: The Start of a Beautiful Relationship.Journal of clinical medicine · 2022Review
- Corneal Confocal Microscopy and the Nervous System: Introduction to the Special Issue.Journal of clinical medicine · 2022Article
- A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan.Frontiers in cardiovascular medicine · 2022Article
- Targeting the innate repair receptor axisFrontiers in immunology · 2022Article
- Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice.Frontiers in pharmacology · 2022Article
- The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice.International journal of molecular sciences · 2021Article
- Systemic diseases and the cornea.Experimental eye research · 2021Review
- Improvements in Diabetic Neuropathy and Nephropathy After Bariatric Surgery: a Prospective Cohort Study.Obesity surgery · 2021Observational
- Corneal Confocal Microscopy to Image Small Nerve Fiber Degeneration: Ophthalmology Meets Neurology.Frontiers in pain research (Lausanne, Switzerland) · 2021Review
- Erythropoietin and its derivatives: from tissue protection to immune regulation.Cell death & disease · 2020Review
- Treatment of Sarcoidosis: A Multidisciplinary Approach.Frontiers in immunology · 2020Review
- Neuropathic Pain: Challenges and Opportunities.Frontiers in pain research (Lausanne, Switzerland) · 2020Article
- Management of neurosarcoidosis: a clinical challenge.Current opinion in neurology · 2019Review
Corrections and comments
- Commented on byEditorial.2013
- Erratum issuedERRATUM.2016
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small nerve fiber loss and damage (SNFLD) is a frequent complication of sarcoidosis that is associated with autonomic dysfunction and sensory abnormalities, including pain syndromes that severely degrade the quality of life. SNFLD is hypothesized to arise from the effects of immune dysregulation, an essential feature of sarcoidosis, on the peripheral and central nervous systems. Current therapy of sarcoidosis-associated SNFLD consists primarily of immune suppression and symptomatic treatment; however, this treatment is typically unsatisfactory. ARA 290 is a small peptide engineered to activate the innate repair receptor that antagonizes inflammatory processes and stimulates tissue repair. Here we show in a blinded, placebo-controlled trial that 28 d of daily subcutaneous administration of ARA 290 in a group of patients with documented SNFLD significantly improves neuropathic symptoms. In addition to improved patient-reported symptom-based outcomes, ARA 290 administration was also associated with a significant increase in corneal small nerve fiber density, changes in cutaneous temperature sensitivity, and an increased exercise capacity as assessed by the 6-minute walk test. On the basis of these results and of prior studies, ARA 290 is a potential disease-modifying agent for treatment of sarcoidosis-associated SNFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.